Clinical Trials · NCT06671587
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Sanofi
- Enrollment
- 678
- Start date
- Dec 2024
- Locations
- 1 site, China
- Primary endpoint
- Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]